About kamada ltd - KMDA
Kamada Ltd. is a biopharmaceutical company, which focuses on specialty plasma-derived therapeutic. It operates through the Proprietary Products and Distribution segments. The Proprietary Products segment refers to specialty plasma therapies and normal source plasma ("NSP"). The Distribution segment focuses on the commercialization of in-licensed third-party biopharmaceutical products. The company was founded by David Tsur and Ralf Hahn on December 13, 1990 and is headquartered in Rehovot, Israel.
KMDA At a Glance
Kamada Ltd.
Science Park
Rehovot, HaMerkaz 7670402
| Phone | 972-8-940-6472 | Revenue | 180.46M | |
| Industry | Biotechnology | Net Income | 20.20M | |
| Sector | Health Technology | 2025 Sales Growth | 12.12% | |
| Fiscal Year-end | 12 / 2026 | Employees | 462 | |
| View SEC Filings |
KMDA Valuation
| P/E Current | 22.142 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 20.237 |
| Price to Sales Ratio | 2.293 |
| Price to Book Ratio | 1.52 |
| Price to Cash Flow Ratio | 16.23 |
| Enterprise Value to EBITDA | 8.501 |
| Enterprise Value to Sales | 1.939 |
| Total Debt to Enterprise Value | 0.033 |
KMDA Efficiency
| Revenue/Employee | 390,606.061 |
| Income Per Employee | 43,718.615 |
| Receivables Turnover | 6.214 |
| Total Asset Turnover | 0.481 |
KMDA Liquidity
| Current Ratio | 4.074 |
| Quick Ratio | 2.282 |
| Cash Ratio | 1.592 |
KMDA Profitability
| Gross Margin | 40.075 |
| Operating Margin | 14.537 |
| Pretax Margin | 13.004 |
| Net Margin | 11.193 |
| Return on Assets | 5.379 |
| Return on Equity | 7.643 |
| Return on Total Capital | 7.197 |
| Return on Invested Capital | 7.38 |
KMDA Capital Structure
| Total Debt to Total Equity | 4.297 |
| Total Debt to Total Capital | 4.12 |
| Total Debt to Total Assets | 3.053 |
| Long-Term Debt to Equity | 3.508 |
| Long-Term Debt to Total Capital | 3.364 |